French-German Cooperation to Improve Personalized Cancer Care
By LabMedica International staff writers Posted on 27 Oct 2014 |
A leading French oncology center will be collaborating with a German manufacturer of molecular diagnostic tests to develop new approaches to personalized cancer care.
The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes 20% of its budget to research, will be cooperating with New Oncology (Cologne, Germany), the molecular diagnostics division of Blackfield AG (Cologne, Germany), a biotechnology company focusing on genome analytics, discovering modifiers of drug response, and developing next-generation diagnostics.
New Oncology developed the proprietary diagnostic platform NEOplus. This is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA. In addition, NEOplus is suited to analyzing all solid tumor types.
“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Dr. Jean-Charles Soria, head of the drug development department at Gustave Roussy Cancer Campus.
“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients,” said Dr. Andreas Jenne, CEO of New Oncology.
Related Links:
Gustave Roussy Cancer Campus
New Oncology
Blackfield AG
The Gustave Roussy Cancer Campus (Paris, France), a medical center with 2,600 health professionals dedicated to cancer diagnosis and treatment that devotes 20% of its budget to research, will be cooperating with New Oncology (Cologne, Germany), the molecular diagnostics division of Blackfield AG (Cologne, Germany), a biotechnology company focusing on genome analytics, discovering modifiers of drug response, and developing next-generation diagnostics.
New Oncology developed the proprietary diagnostic platform NEOplus. This is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA. In addition, NEOplus is suited to analyzing all solid tumor types.
“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Dr. Jean-Charles Soria, head of the drug development department at Gustave Roussy Cancer Campus.
“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients,” said Dr. Andreas Jenne, CEO of New Oncology.
Related Links:
Gustave Roussy Cancer Campus
New Oncology
Blackfield AG
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance